These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 15695408)
1. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408 [TBL] [Abstract][Full Text] [Related]
2. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277 [TBL] [Abstract][Full Text] [Related]
3. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. Sensi M; Pietra G; Molla A; Nicolini G; Vegetti C; Bersani I; Millo E; Weiss E; Moretta L; Mingari MC; Anichini A Int Immunol; 2009 Mar; 21(3):257-68. PubMed ID: 19181932 [TBL] [Abstract][Full Text] [Related]
4. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966 [TBL] [Abstract][Full Text] [Related]
5. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334 [TBL] [Abstract][Full Text] [Related]
7. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. Riley JP; Rosenberg SA; Parkhurst MR J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498 [TBL] [Abstract][Full Text] [Related]
8. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905 [TBL] [Abstract][Full Text] [Related]
9. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401 [TBL] [Abstract][Full Text] [Related]
10. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698 [TBL] [Abstract][Full Text] [Related]
11. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999 [TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955 [TBL] [Abstract][Full Text] [Related]
13. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24. Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648 [TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391 [TBL] [Abstract][Full Text] [Related]
15. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612 [TBL] [Abstract][Full Text] [Related]
16. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. Yee C; Gilbert MJ; Riddell SR; Brichard VG; Fefer A; Thompson JA; Boon T; Greenberg PD J Immunol; 1996 Nov; 157(9):4079-86. PubMed ID: 8892642 [TBL] [Abstract][Full Text] [Related]
17. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155 [TBL] [Abstract][Full Text] [Related]
18. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Ayyoub M; Zippelius A; Pittet MJ; Rimoldi D; Valmori D; Cerottini JC; Romero P; Lejeune F; Liénard D; Speiser DE Clin Cancer Res; 2003 Feb; 9(2):669-77. PubMed ID: 12576434 [TBL] [Abstract][Full Text] [Related]
19. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Chiari R; Foury F; De Plaen E; Baurain JF; Thonnard J; Coulie PG Cancer Res; 1999 Nov; 59(22):5785-92. PubMed ID: 10582700 [TBL] [Abstract][Full Text] [Related]
20. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer. Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]